Solid Biosciences reports Q3 net loss $21M vs $20.4M last year

Reports Solid had $142.9 M in cash, cash equivalents, and available-for-sale securities as of September 30, compared to $213.7M as of December 31, 2022. The Company expects that its cash, cash equivalents, and available-for-sale securities will enable it to fund key strategic priorities through multiple important pipeline milestones and into 2025..”We are pleased with the continued advancement of our diversified pipeline of neuromuscular and cardiac gene therapies; including an IND submission in this quarter for SGT-003 for patients with Duchenne,” said Bo Cumbo, President and CEO of Solid Biosciences. “We continue to expand our pipeline and last quarter licensed in a gene transfer program to treat catecholaminergic polymorphic ventricular tachycardia CPVT . With the addition of Dr. Gabriel Brooks as our Chief Medical Officer and his specialized background in cardiology, we hope to accelerate our multiple cardiac and neuromuscular pipeline assets in preclinical development. Our commitment to bringing transformational therapies to address the severe unmet needs of patients, their caregivers, and families, remains steadfast.”